• Agenus reported peer-reviewed updated Phase 2 NEST results for pre-surgery botensilimab with balstilimab in resectable colon cancer.
• Earlier findings were presented at the 2025 ASCO Gastrointestinal Cancers Symposium; the new publication adds longer follow-up through March 31, 2026.
• Updated data showed deep tumor shrinkage with no observed colorectal cancer recurrences during follow-up.
• Most evaluable patients cleared circulating tumor DNA before surgery; treatment did not disrupt planned surgical timing.
• Results underpin the planned global Phase 3 ROBBIN trial in high-risk Stage II or Stage III MSS colon cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608261005BIZWIRE_USPR_____20260826_BW183640) on August 26, 2026, and is solely responsible for the information contained therein.